SITE011-0083

SITE011 (ITA) › SITE011-0083

SITE011-0083

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2025-11-30

enrolled

AEs

6

Serious

0

Dropout signal

–

Adverse events

6

Grade 1 Nausea — outcome: UNKNOWN; onset 2023-02-12 (study day 249); relationship: not assessed

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-22 (study day 197); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: UNKNOWN; onset 2022-11-01 (study day 146); relationship: NOT RELATED

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-24 (study day 138); relationship: RELATED

mild assessed

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-01 (study day 54); relationship: not assessed

moderate assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 53); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.